Switch to:
More From Other Websites
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study Feb 27 2017
5:51 am AbbVie confirms that the CHMP granted a positive opinion for a shorter, eight-week treatment... Feb 27 2017
AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX®... Feb 27 2017
Facing Criticism, Drug Makers Keep Lid On Price Increases Feb 27 2017
Drug Companies Keep Lid on Price Increases Feb 26 2017
Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink Feb 24 2017
2 Dividend Aristocrats Trading At A Discount Feb 23 2017
AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink Feb 23 2017
ABBVIE INC. Financials Feb 23 2017
Questions Linger About AbbVie's AndroGel Feb 23 2017
AbbVie Declares Quarterly Dividend Feb 21 2017
AbbVie Inc (ABBV) In Share Buyback Plan For The Third Year In A Row Feb 21 2017
AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : February 21, 2017 Feb 21 2017
ABBVIE INC. Files SEC form 10-K, Annual Report Feb 17 2017
Parsabiv Is Expected to Boost Amgen’s Revenues in 2017 Feb 17 2017
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira Feb 17 2017
AbbVie Announces $5 Billion Increase to Stock Repurchase Program Feb 17 2017
NICE Rejects AbbVie’s Leukemia Drug Venclexta Feb 16 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK